Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism.

BACKGROUND Parkinson disease (PD) is characterized by loss of dopaminergic neurons in the substantia nigra. Genes contributing to rare mendelian forms of PD have been identified, but the genes involved in the more common idiopathic PD are not well understood. OBJECTIVES To identify genes important to PD pathogenesis using microarrays and to investigate their potential to aid in diagnosing parkinsonism. DESIGN Microarray expression analysis of postmortem substantia nigra tissue. PATIENTS Substantia nigra samples from 14 unrelated individuals were analyzed, including 6 with PD, 2 with progressive supranuclear palsy, 1 with frontotemporal dementia with parkinsonism, and 5 control subjects. MAIN OUTCOME MEASURES Identification of genes significantly differentially expressed (P<.05) using Affymetrix U133A microarrays. RESULTS There were 142 genes that were significantly differentially expressed between PD cases and controls and 96 genes that were significantly differentially expressed between the combined progressive supranuclear palsy and frontotemporal dementia with parkinsonism cases and controls. The 12 genes common to all 3 disorders may be related to secondary effects. Hierarchical cluster analysis after exclusion of these 12 genes differentiated 4 of the 6 PD cases from progressive supranuclear palsy and frontotemporal dementia with parkinsonism. CONCLUSIONS Four main molecular pathways are altered in PD substantia nigra: chaperones, ubiquitination, vesicle trafficking, and nuclear-encoded mitochondrial genes. These results correlate well with expression analyses performed in several PD animal models. Expression analyses have promising potential to aid in postmortem diagnostic evaluation of parkinsonism.

[1]  F. Dietrich,et al.  Genomic convergence to identify candidate genes for Parkinson disease: SAGE analysis of the substantia nigra , 2005, Movement disorders : official journal of the Movement Disorder Society.

[2]  Eden R Martin,et al.  Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. , 2003, Human molecular genetics.

[3]  Susan Lindquist,et al.  Yeast Genes That Enhance the Toxicity of a Mutant Huntingtin Fragment or α-Synuclein , 2003, Science.

[4]  T. Dawson,et al.  Molecular Pathways of Neurodegeneration in Parkinson's Disease , 2003, Science.

[5]  Clemens R Scherzer,et al.  Gene expression changes presage neurodegeneration in a Drosophila model of Parkinson's disease. , 2003, Human molecular genetics.

[6]  Eden Martin,et al.  Genomic convergence: identifying candidate genes for Parkinson's disease by combining serial analysis of gene expression and genetic linkage. , 2003, Human molecular genetics.

[7]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[8]  P. Lansbury,et al.  The UCH-L1 Gene Encodes Two Opposing Enzymatic Activities that Affect α-Synuclein Degradation and Parkinson's Disease Susceptibility , 2002, Cell.

[9]  B. Davletov,et al.  Vesicular restriction of synaptobrevin suggests a role for calcium in membrane fusion , 2002, Nature.

[10]  John Q. Trojanowski,et al.  Chaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease , 2001, Science.

[11]  J. Haines,et al.  Complete genomic screen in Parkinson disease: evidence for multiple genes. , 2001, JAMA.

[12]  N. Morel,et al.  Neurotransmitter release through the V0 sector of V‐ATPase , 2001, Journal of neurochemistry.

[13]  C. Hulette,et al.  Recovery and Expression of Messenger RNA from Postmortem Human Brain Tissue , 2001, Modern Pathology.

[14]  T. Südhof,et al.  Synaptotagmin I functions as a calcium regulator of release probability , 2001, Nature.

[15]  W. Bender,et al.  A Drosophila model of Parkinson's disease , 2000, Nature.

[16]  M. Pericak-Vance,et al.  Neuropathological features of frontotemporal dementia and parkinsonism linked to chromosome 17q21-22 (FTDP-17): Duke Family 1684. , 1999, Journal of neuropathology and experimental neurology.

[17]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[18]  G. Halliday,et al.  Progressive Supranuclear Palsy Affects both the Substantia Nigra Pars Compacta and Reticulata , 1997, Experimental Neurology.

[19]  I Litvan,et al.  Validity and Reliability of the Preliminary NINDS Neuropathologic Criteria for Progressive Supranuclear Palsy and Related Disorders , 1996, Journal of neuropathology and experimental neurology.

[20]  Mrc Psych,et al.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop , 1996 .

[21]  C. Finch,et al.  Extensive postmortem stability of RNA from rat and human brain , 1986, Journal of neuroscience research.